CX-052075 is an mRNA vaccine encoding the N-terminal and receptor-binding domains of the spike protein of SARS-CoV-2 Omicron variant sublineage LP.8.1. It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna.
- Mechanism
- Curator reviewed · 1 reference
CX-052075 is a nucleoside-modified mRNA, encapsulated in lipid nanoparticles, encoding the N-terminal domain and the receptor-binding domain of the spike protein of SARS-CoV-2 Omicron variant sublineage LP.8.1. The administration of CX-052075 elicits an immune response against the SARS-CoV-2 spike protein which provides protection against COVID-19.
- Primary indication
- CX-052075 - as the primary ingredient in mNEXSPIKE - is indicated for active immunization against COVID-19 caused by SARS-CoV-2 in patients who have been previously vaccinated and who are ≥65 years of age or 12-64...Curator reviewed · 2 structured indications
- First approval
- United States, 2025
- Also known as
- mNEXSPIKE (2025-2026 Formula)
- Code names
- CX-052075
Resolves to
What you can answer from here — as of June 19, 2026
Which other approved drugs treat the same conditions as CX-052075, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account